Sanofi, a French multinational pharmaceutical company, acquired Bioverativ, an American multinational biotechnology that specializes in the discovery, development, and delivery of therapies for the treatment of haemophilia, for $10.8bn. “With Bioverativ, a leader in the growing hemophilia market, Sanofi enhances its presence in specialty care and leadership in rare diseases, in line with its 2020 Roadmap, and creates a platform for growth in other rare blood disorders. Together, we have a great opportunity to bring innovative medicines to patients worldwide, building on Bioverativ’s success in driving new standards of care with its extended half-life factor replacement therapies. Combined, we will continue to leverage our scientific know-how, disciplined focus and development expertise that best position us to drive value for our shareholders and create breakthrough treatments for patients.” Olivier Brandicourt, Sanofi’s Chief Executive Officer.